Business
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -- Dermata recently completed
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -- Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 -- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy - SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) (\"Dermata\" or the \"Company\"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced receipt of a notice of allowance from the United States Patent and Trademark Office of a new patent for its DMT310 product candidate for the treatment of acne. The allowed patent application, entitled \"Compositions and methods for the treatment of skin conditions\" (U.S. Application No. 17/420,635), further strengthens Dermata's intellectual property for DMT310. \"We are thrilled to receive this notice of allowance in the U.S., which we believe further validates DMT310's novel approach to treat acne with a once weekly topical product,\" commented Gerry Proehl, Dermata's Chairman, President, and CEO. \"Given the unique features and benefits of DMT310, we believe, if approved, it could potentially transform the current acne treatment guidelines and allow DMT310 to be a first-line treatment option. We also recently completed enrollment in the first of two DMT310 Phase 3 studies and are eager to announce topline results in March of 2025. We look forward to this allowed patent application eventually advancing to issuance and support our intellectual property protections for DMT310.\"About DMT310DMT310 is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases. DMT310 has multiple mechanisms of action that include mechanical components and chemical compounds to help treat inflammatory skin diseases, like acne. After processing, the sponge powder contains precisely sized and shaped silica spicules that upon application may help exfoliate the skin, promote collagen production, open closed comedones (creating an aerobic environment to help kill C. acne bacteria), and create microchannels to faci...